2024 Fall Conference | Industry Therapeutic Update from Biogen: SKYCLARYS® (omaveloxolone) The First and Only FDA-Approved Prescription Treatment for Friedreich Ataxia in Adults and Adolescents Aged 16 Years and Older

Date Saturday 10/26/24

Time 07:00 AM - 07:50 AM PDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology, Movement Disorders

Learning Objectives This presentation will include an introduction into the clinical background of Friedreich Ataxia (FA), a summary of the clinical efficacy and safety data from the clinical trials that studied SKYCLARYS in the treatment of FA, and the clinical management of treatment with SKYCLARYS.

This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:50 AM PDT	Speaker	Industry Therapeutic Update from Biogen: SKYCLARYS® (omaveloxolone) The First and Only FDA-Approved Prescription Treatment for Friedreich Ataxia in Adults and Adolescents Aged 16 Years and Older

��ɫ��

��ɫ��